Affimed NV (Affimed NV) Debt-to-Equity : 0.34 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Affimed NV Debt-to-Equity?

Affimed NV's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $6.95 Mil. Affimed NV's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $14.15 Mil. Affimed NV's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $63.04 Mil. Affimed NV's debt to equity for the quarter that ended in Dec. 2023 was 0.33.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Affimed NV's Debt-to-Equity or its related term are showing as below:

AFMD' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.12 Max: 0.34
Current: 0.34

During the past 12 years, the highest Debt-to-Equity Ratio of Affimed NV was 0.34. The lowest was 0.02. And the median was 0.12.

AFMD's Debt-to-Equity is ranked worse than
68.07% of 1071 companies
in the Biotechnology industry
Industry Median: 0.15 vs AFMD: 0.34

Affimed NV Debt-to-Equity Historical Data

The historical data trend for Affimed NV's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Affimed NV Debt-to-Equity Chart

Affimed NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.08

0.02

0.14

0.12

0.34

Affimed NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.12	0.13	0.15	0.28	0.34

Competitive Comparison of Affimed NV's Debt-to-Equity

For the Biotechnology subindustry, Affimed NV's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Affimed NV's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Affimed NV's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Affimed NV's Debt-to-Equity falls into.

Affimed NV Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Affimed NV's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.949	+	14.154)	/	63.039
	=	0.33

Affimed NV's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(6.949	+	14.154)	/	63.039
	=	0.33

Affimed NV (NAS:AFMD) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Affimed NV Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Affimed NV's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Affimed NV (Affimed NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Affimed NV (NAS:AFMD) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

A28:Germany

Address

Im Neuenheimer Feld 582, Technologiepark, Heidelberg, BW, DEU, 69120

Website

https://www.affimed.com

Affimed NV is a clinical-stage biopharmaceutical company. The company is engaged in discovering and developing targeted cancer immunotherapies. Its product candidates are being developed in the field of immuno-oncology, which represents an approach to cancer treatment that seeks to harness the body's immune defenses to fight tumor cells. The company is also developing single and combination therapies to treat cancers and other life-threatening diseases. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe and Germany.